Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety and to determine the
appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with
type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration
once daily in multi-center, randomized, double-blind, placebo-controlled, parallel assignment
manner.